menu
    • menu
    [{"orgOrder":0,"company":"Kaneka Corporation","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Enzyme","year":"2014","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"Mitochondrial electron transport chain","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Kaneka Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaneka Corporation \/ Kaneka Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Kaneka Corporation \/ Kaneka Corporation"},{"orgOrder":0,"company":"Kaneka Corporation","sponsor":"Beth Israel Deaconess Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2013","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"Mitochondrial electron transport chain","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Kaneka Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Kaneka Corporation \/ Kaneka Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Kaneka Corporation \/ Kaneka Corporation"},{"orgOrder":0,"company":"Kaneka Corporation","sponsor":"Beth Israel Deaconess Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2016","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"Mitochondrial electron transport chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Kaneka Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Kaneka Corporation \/ Kaneka Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Kaneka Corporation \/ Kaneka Corporation"},{"orgOrder":0,"company":"Kaneka Corporation","sponsor":"Kaneka Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"JAPAN","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Chrysanthemum Flower Oil","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Undisclosed","graph3":"Kaneka Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaneka Corporation \/ Kaneka Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Kaneka Corporation \/ Kaneka Corporation"},{"orgOrder":0,"company":"Kaneka Corporation","sponsor":"Kaneka Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Lactobacillus Plantarum (Cect7484 And Cect7485)","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Kaneka Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaneka Corporation \/ Kaneka Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Kaneka Corporation \/ Kaneka Corporation"},{"orgOrder":0,"company":"Kaneka Corporation","sponsor":"Kaneka Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2019","type":"Inapplicable","leadProduct":"Mermed One","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Kaneka Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaneka Corporation \/ Kaneka Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Kaneka Corporation \/ Kaneka Corporation"}]

    Find Clinical Drug Pipeline Developments & Deals by Kaneka Corporation

    Menu

    Kaneka Corporation

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kaneka Corporation

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Kaneka Corporation

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lactobacillus Plantarum (Cect7484 And Cect7485)

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Recipient : Scripps Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effects of a Multispecies Probiotic on Migraine

                            Details : Lactobacillus Plantarum (Cect7484 And Cect7485) is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Migraine Disorders.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 06, 2021

                            Lead Product(s) : Lactobacillus Plantarum (Cect7484 And Cect7485)

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Recipient : Scripps Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kaneka Corporation

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Kaneka Corporation

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mermed One

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Recipient : University of Nottingham

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparison of an Alginate Containing Enteral Feed and an Alginate Free Enteral Feed.

                            Details : Mermed One is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            October 02, 2019

                            Lead Product(s) : Mermed One

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Recipient : University of Nottingham

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Kaneka Corporation

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Kaneka Corporation

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Coenzyme Q10

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Recipient : Beth Israel Deaconess Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ubiquinol as a Metabolic Resuscitator in Post-Cardiac Arrest

                            Details : Ubiquinol is a Enzyme drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Heart Arrest.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            October 17, 2016

                            Lead Product(s) : Coenzyme Q10

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Recipient : Beth Israel Deaconess Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Kaneka Corporation

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Kaneka Corporation

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Coenzyme Q10

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase I

                            Recipient : Massachusetts General Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Assessing Bioavailability of CoQ10 Supplementation in Burn Patients

                            Details : Coenzyme Q10 is a Enzyme drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Burns.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            September 29, 2014

                            Lead Product(s) : Coenzyme Q10

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase I

                            Recipient : Massachusetts General Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Kaneka Corporation

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Kaneka Corporation

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chrysanthemum Flower Oil

                            Therapeutic Area : Rheumatology

                            Study Phase : Undisclosed

                            Recipient : Hiroshima University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Chrysanthemum Flower Oil and Its Dose-dependency on Hyperuricemia

                            Details : Chrysanthemum Flower Oil is a Plant Extract/Herbal drug candidate, which is currently being evaluated in clinical studies for the treatment of Hyperuricemia.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            August 11, 2014

                            Lead Product(s) : Chrysanthemum Flower Oil

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Undisclosed

                            Recipient : Hiroshima University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Kaneka Corporation

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Kaneka Corporation

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Coenzyme Q10

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Recipient : Beth Israel Deaconess Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ubiquinol (Reduced COQ10) for Patients With Sepsis

                            Details : Ubiquinol is a Enzyme drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Sepsis.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            September 23, 2013

                            Lead Product(s) : Coenzyme Q10

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Recipient : Beth Israel Deaconess Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth